[Impact of resistance to analogue antivirals and therapeutic strategies in situations of dialysis, kidney transplantation, vasculitis, and preemptive treatments in immunosuppressed patients].
Pol
Stanislas
S
Unité d'Hépatologie et INSERM U-370, Hôpital Necker, 149, rue de Sèvres, 75015 Paris, France.
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics*; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000150:complications / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006801:Humans; D016867:Immunocompromised Host; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D016030:Kidney Transplantation; D019259:Lamivudine / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D006435:Renal Dialysis / Q000379:methods; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D014657:Vasculitis / Q000209:etiology / Q000628:therapy*
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C053001:adefovir; D000225:Adenine